Dr. Cunnion is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
601 Childrens Ln
Norfolk, VA 23507Phone+1 757-668-7238Fax+1 757-668-8275- Is this information wrong?
Education & Training
- Duke University HospitalFellowship, Pediatric Infectious Diseases, 1996 - 2000
- Virginia Commonwealth University Health SystemResidency, Pediatrics, 1993 - 1996
- Duke University School of MedicineClass of 1993
Certifications & Licensure
- VA State Medical License 1995 - 2024
- NC State Medical License 1997 - 2003
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Infectious Diseases
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Fellow (FAAP) American Academy of Pediatrics
Publications & Presentations
PubMed
- RLS-0071 Moderated Elevated Myeloperoxidase Level and Activity in an Asymptomatic Subject in Clinical Trial RLS-0071-101.Jessica M Goss, Pamela Hair, Parvathi S Kumar, Ulrich Thienel, Kenji Cunnion, Alexander Ellis> ;The American Journal of Case Reports. 2023 May 26
- The EPICC Family of Anti-Inflammatory Peptides: Next Generation Peptides, Additional Mechanisms of Action, andandEfficacy.Neel K Krishna, Kenji M Cunnion, Grace A Parker> ;Frontiers in Immunology. 2022 Jan 1
- 2 citationsPeptide inhibition of acute lung injury in a novel two-hit rat modelAlana C. Sampson, Brittany P. Lassiter, Magdielis Gregory Rivera, Pamela S. Hair, Kaitlyn G. Jackson, Adrianne I. Enos, Turaj Vazifedan, Alice L. Werner, Marshall J. G...> ;Plos One. 2021 Oct 28
- Join now to see all
Press Mentions
- ReAlta Life Sciences Announces Dosing of First Patient in Phase 2 Trial of RLS-0071 for Acute Exacerbations of Chronic Obstructive Pulmonary DiseaseFebruary 22nd, 2024
- ReAlta Life Sciences, Inc. Doses First Patient in Phase 1b Inhaled-LPS Challenge Clinical Trial to Support Development of RLS-0071 in Severe AsthmaJune 4th, 2022
- Trial of RLS-0071 for Acute COPD Exacerbations Doses 1st PatientMarch 5th, 2024
Grant Support
- Staphylococcus Aureus Binds Factor H To Moderate Complement Host DefenseNational Institute Of Allergy And Infectious Diseases2009–2010
- Complement And The Clearance Of Staphylococcus AureusNational Institute Of Allergy And Infectious Diseases2002–2006
- Complement And The Clearance Of Staphylococcus AureusNational Institute Of Allergy And Infectious Diseases2002
Professional Memberships
- Fellow
Hospital Affiliations
- Children's Hospital of The King's DaughtersNorfolk, Virginia
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: